CN112646193A - 一种块状双膦酸钙配合物及其制备方法 - Google Patents
一种块状双膦酸钙配合物及其制备方法 Download PDFInfo
- Publication number
- CN112646193A CN112646193A CN202011608810.7A CN202011608810A CN112646193A CN 112646193 A CN112646193 A CN 112646193A CN 202011608810 A CN202011608810 A CN 202011608810A CN 112646193 A CN112646193 A CN 112646193A
- Authority
- CN
- China
- Prior art keywords
- calcium
- complex
- diphosphonic acid
- hydroxy
- biphosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 title claims abstract description 23
- 229910000389 calcium phosphate Inorganic materials 0.000 title claims abstract description 23
- 235000019691 monocalcium phosphate Nutrition 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 238000010668 complexation reaction Methods 0.000 title description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims abstract description 24
- 239000013078 crystal Substances 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000011575 calcium Substances 0.000 claims abstract description 18
- 229910001868 water Inorganic materials 0.000 claims abstract description 18
- -1 imidazole-1-yl Chemical group 0.000 claims abstract description 15
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 10
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 8
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims abstract description 8
- 239000000126 substance Substances 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 239000008367 deionised water Substances 0.000 claims abstract description 3
- 229910021641 deionized water Inorganic materials 0.000 claims abstract description 3
- 239000002904 solvent Substances 0.000 claims abstract description 3
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 230000035484 reaction time Effects 0.000 claims description 6
- 238000005406 washing Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- 239000001110 calcium chloride Substances 0.000 claims description 4
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 4
- WPSNYFRQPAASHJ-UHFFFAOYSA-J [Ca+2].[Ca+2].[O-]P([O-])=O.[O-]P([O-])=O Chemical compound [Ca+2].[Ca+2].[O-]P([O-])=O.[O-]P([O-])=O WPSNYFRQPAASHJ-UHFFFAOYSA-J 0.000 claims description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 3
- 239000000920 calcium hydroxide Substances 0.000 claims description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 3
- 239000001506 calcium phosphate Substances 0.000 claims description 3
- 235000011010 calcium phosphates Nutrition 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 3
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000012010 growth Effects 0.000 abstract description 3
- 230000017423 tissue regeneration Effects 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 16
- 229930182555 Penicillin Natural products 0.000 description 10
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 10
- 229940049954 penicillin Drugs 0.000 description 10
- 239000003446 ligand Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940122361 Bisphosphonate Drugs 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 150000004663 bisphosphonates Chemical class 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000013256 coordination polymer Substances 0.000 description 2
- 229920001795 coordination polymer Polymers 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027067 Paget disease of bone Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical group OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000016738 bone Paget disease Diseases 0.000 description 1
- 230000010478 bone regeneration Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229910000393 dicalcium diphosphate Inorganic materials 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000005232 molecular self-assembly Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/008—Supramolecular polymers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
本发明公开了一种块状双膦酸钙配合物及其制备方法,其化学式为Ca(2Zol)(2H2O),其中Ca表示钙,Zol表示1‑羟基‑2‑(咪唑‑1‑基)‑亚乙基‑1,1‑二磷酸,H2O表示水,晶系为三斜晶系,空间群为P‑1,晶格常数为 α=105.648,β=109.149°,γ=97.8570°,z=1。本发明是以钙盐和1‑羟基‑2‑(咪唑‑1‑基)‑亚乙基‑1,1‑二磷酸为原料,以去离子水为溶剂,用氢氧化钠溶液调节pH至2.5‑3.5,于20‑30℃下静置20‑60天,再过滤、洗涤和干燥,得到块状透明晶体,即为块状双膦酸钙配合物。本发明制备方法极为简单,晶体生长速度适中,应力小,均匀性好且具有非常完整的外形,在药物缓释、靶向输运及骨组织修复等领域都具有重要的潜在应用前景。
Description
技术领域
本发明涉及生物医学材料的技术领域,尤其是指一种块状双膦酸钙配合物及其制备方法。
背景技术
配位聚合物是一类由金属离子和有机配体通过配位键结合形成的化合物。近年来,配位聚合物化学的发展赋予其在设计、合成、结构、性能等领域新的探索与应用,逐渐成为有机、无机、材料、生物、医学等学科的前沿和热点课题。利用分子自组装原理来设计和构筑具有新颖结构的配合物,使其具有特定的生物学功能,对其在生物医学领域广阔的应用具有重要的现实意义。
1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸是一种广泛应用于临床上抗骨质疏松、变形性骨炎、骨相关肿瘤的双膦酸类小分子药物。但是,当前双膦酸(或钠盐)水溶性比较强,而其发挥有效作用的浓度阈值很低,超过阈值容易引发不良反应,因而通常只能进行直接注射或使用递送***进行负载缓释,一定程度上限制了双膦酸盐这类成骨效果显著的分子在骨再生修复中的应用。因而,寻找显著低于双膦酸(或钠盐)的溶解度或降解速率的其它双膦酸盐对于其在骨修复领域进一步推广应用具有非常重要的意义。
双膦酸结构含有两个膦酸根,在水中电离后的离子形态大多是两齿或多齿配体,极易与钙离子等多配位金属离子螯合,形成一类物理化学性质稳定且不易溶解的金属有机配合物,从而实现双膦酸分子在水溶液中的缓慢释放。因此,该配合物势必在材料科学和生物医学等领域具有潜在的应用价值。所以我们以1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸为配体和钙离子反应,制得块状双膦酸钙配合物,制备方法极为简单,晶体生长速度适中,应力小,均匀性好且具有非常完整的外形,不易溶解在水中,在药物缓释,靶向输运及骨组织修复等领域都具有重要的潜在应用前景。
发明内容
本发明的目的在于克服现有技术的缺点与不足,提出了一种块状双膦酸钙配合物及其制备方法,通过静置法制备得到的块状双膦酸钙配合物,制备方法极为简单,晶体生长速度适中,应力小,均匀性好且具有非常完整的外形,在药物缓释、靶向输运及骨组织修复等领域都具有重要的潜在应用前景。
为实现上述目的,本发明所提供的技术方案为:一种块状双膦酸钙配合物,其化学式为Ca(2Zol)(2H2O),其中Ca表示钙,Zol表示1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸,H2O表示水,晶系为三斜晶系,空间群为P-1,晶格常数为α=105.648,β=109.149°,γ=97.8570°,z=1。
进一步,其在水溶液中形貌为无色透明块状多面体,且随着pH的升高,尺寸越来越小。
本发明也提供了上述块状双膦酸钙配合物的制备方法,该方法是以钙盐和1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸为原料,以去离子水为溶剂,用氢氧化钠溶液调节pH至2.5-3.5,于20-30℃下静置20-60天,再过滤、洗涤和干燥,得到块状透明晶体,即为块状双膦酸钙配合物;其中,反应时间和反应温度呈负相关,即温度越高,反应时间越短。
进一步,所述1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸的浓度为10-30mmol/L。
进一步,所述钙盐和1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸的摩尔比为1:2~2:1。
进一步,所述钙盐为氯化钙、硝酸钙、氢氧化钙、磷酸钙中的任意一种。
本发明与现有技术相比,具有如下优点与有益效果:
本发明以钙盐和1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸为原料,采用静置法制备的块状双膦酸钙配合物,制备方法极为简单,晶体生长速度适中,应力小,均匀性好且具有非常完整的外形。该配合物以钙为中心原子,1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸为桥连配体,呈现空间一维直链状结构。该块状双膦酸钙配合物在药物缓释、靶向输运及骨组织修复等领域都具有重要的潜在应用前景,值得推广。
附图说明
图1为块状双膦酸钙配合物的晶体图。
图2为块状双膦酸钙配合物的结构单元图。
具体实施方式
下面结合实施例及附图对本发明作进一步详细的描述,但本发明的实施方式不限于此。
实施例1
称取纯度为98%的1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸(0.0272g,0.10mmol)、纯度为98%的氯化钙(0.0110g,0.10mmol),加入10mL水中,缓慢滴入0.1mol/LNaOH溶液,同时搅拌使溶液澄清透明并调节pH至2.5,然后将溶液转移到西林瓶中,盖好,拧紧,将西林瓶置于恒温箱中,于20℃下反应60天,随后过滤,洗涤,干燥,得到较大的形状规则的无色透明块状晶体,即为块状双膦酸钙配合物。其中,制备过程的反应时间和反应温度呈负相关,即温度越高,反应时间越短;制备的块状双膦酸钙配合物在水溶液中形貌为无色透明块状晶体,且随着pH的升高,尺寸越来越小。
图1为块状双膦酸钙配合物晶体的光学显微镜图,从图中可以看出该块状双膦酸钙配合物为无色透明块状晶体。
对1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸钙晶体进行单晶测试及解析,得到该配合物的结构单元图,如图2所示,该块状双膦酸钙配合物的化学式为Ca(Zol)(H2O)·2H2O,其中Ca表示钙,Zol表示1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸,H2O表示水,晶系为单斜晶系,空间群为P21/N,晶格常数为 β=95.753°,z=4。中心金属钙原子为六配位,分别与4个O(2+2,分别来自两个1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸配体)和2个O(来自水配体)配位,形成八面体结构。
实施例2
称取纯度为98%的1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸(0.0408g,0.15mmol)、纯度为98%的氢氧化钙(0.0074g,0.1mmol),加入10mL水中,缓慢滴入0.1mol/LNaOH溶液,同时搅拌使溶液澄清透明并调节pH至3,然后将溶液转移到西林瓶中,盖好,拧紧,将西林瓶置于恒温箱中,于25℃下反应40天,随后过滤,洗涤,干燥,得到较大的形状规则的无色透明块状晶体,即为块状双膦酸钙配合物。
实施例3
称取纯度为98%的1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸(0.0544g,0.20mmol)、纯度为98%的硝酸钙(0.0164g,0.1mmol),加入10mL水中,缓慢滴入0.1mol/LNaOH溶液,同时搅拌使溶液澄清透明并调节pH至3,然后将溶液转移到西林瓶中,盖好,拧紧,将西林瓶置于恒温箱中,于25℃下反应30天,随后过滤,洗涤,干燥,得到适中的形状规则的无色透明块状晶体,即为块状双膦酸钙配合物。
实施例4
称取纯度为98%的1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸(0.0680g,0.25mmol)、纯度为98%的氯化钙(0.0555g,0.5mmol),加入10mL水中,缓慢滴入0.1mol/LNaOH溶液,同时搅拌使溶液澄清透明并调节pH至3,然后将溶液转移到西林瓶中,盖好,拧紧,将西林瓶置于恒温箱中,于25℃下反应30天,随后过滤,洗涤,干燥,得到适中的形状规则的无色透明块状晶体,即为块状双膦酸钙配合物。
实施例5
称取纯度为98%的1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸(0.0816g,0.30mmol)、纯度为98%的磷酸钙(0.0620g,0.20mmol),加入10mL水中,缓慢滴入0.1mol/LNaOH溶液,同时搅拌使溶液澄清透明并调节pH至3.5,然后将溶液转移到西林瓶中,盖好,拧紧,将西林瓶置于恒温箱中,于30℃下反应20天,随后过滤,洗涤,干燥,得到较小的形状规则的无色透明块状晶体,即为块状双膦酸钙配合物。
上述实施例为本发明较佳的实施方式,但本发明的实施方式并不受上述实施例的限制,其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化,均应为等效的置换方式,都包含在本发明的保护范围之内。
Claims (6)
2.根据权利要求1所述的一种块状双膦酸钙配合物,其特征在于:其在纯水溶液中形貌为无色透明块状多面体,且随着pH的升高,尺寸越来越小。
3.一种权利要求1所述块状双膦酸钙配合物的制备方法,其特征在于:该方法是以钙盐和1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸为原料,以去离子水为溶剂,用氢氧化钠溶液调节pH至2.5-3.5,于20-30℃下静置20-60天,再过滤、洗涤和干燥,得到块状透明晶体,即为块状双膦酸钙配合物;其中,反应时间和反应温度呈负相关,即温度越高,反应时间越短。
4.根据权利要求3所述的一种块状双膦酸钙配合物的制备方法,其特征在于:所述1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸的浓度为10-30mmol/L。
5.根据权利要求3所述的一种块状双膦酸钙配合物的制备方法,其特征在于:所述钙盐和1-羟基-2-(咪唑-1-基)-亚乙基-1,1-二磷酸的摩尔比为1:2~2:1。
6.根据权利要求3或5所述的一种块状双膦酸钙配合物的制备方法,其特征在于:所述钙盐为氯化钙、硝酸钙、氢氧化钙、磷酸钙中的任意一种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011608810.7A CN112646193A (zh) | 2020-12-30 | 2020-12-30 | 一种块状双膦酸钙配合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011608810.7A CN112646193A (zh) | 2020-12-30 | 2020-12-30 | 一种块状双膦酸钙配合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112646193A true CN112646193A (zh) | 2021-04-13 |
Family
ID=75364153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011608810.7A Pending CN112646193A (zh) | 2020-12-30 | 2020-12-30 | 一种块状双膦酸钙配合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112646193A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022142538A1 (zh) * | 2020-12-30 | 2022-07-07 | 华南理工大学 | 一种唑来膦酸钙配合物及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101535323A (zh) * | 2006-11-27 | 2009-09-16 | 诺瓦提斯公司 | 唑来膦酸的晶型 |
-
2020
- 2020-12-30 CN CN202011608810.7A patent/CN112646193A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101535323A (zh) * | 2006-11-27 | 2009-09-16 | 诺瓦提斯公司 | 唑来膦酸的晶型 |
Non-Patent Citations (1)
Title |
---|
ELEONORA FREIRE 等: "Zoledronate complexes. III. Two zoledronate complexes with alkaline earth metals: [Mg(C5H9N2O7P2)2(H2O)2] and [Ca(C5H8N2O7P2)(H2O)]n", 《ACTA CRYST.》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022142538A1 (zh) * | 2020-12-30 | 2022-07-07 | 华南理工大学 | 一种唑来膦酸钙配合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Syntheses and characterizations of a series of novel Ln6Cu24 clusters with amino acids as ligands | |
Fei et al. | Metal− Organic Frameworks Derived from Imidazolium Dicarboxylates and Group I and II Salts | |
Costantino et al. | Preparation, characterization, and structure of zirconium fluoride alkylamino-N, N-bis methylphosphonates: A new design for layered zirconium diphosphonates with a poorly hindered interlayer region | |
Wang et al. | Nature of the reactants and influence of water on the supramolecular assembly | |
Safarifard et al. | Sonochemical synthesis and characterization of nano-sized lead (II) 3D coordination polymer: precursor for the synthesis of lead (II) oxybromide nanoparticles | |
CN112646193A (zh) | 一种块状双膦酸钙配合物及其制备方法 | |
CN112724174A (zh) | 一种薄片状双膦酸钙配合物及其制备方法 | |
CN108384017A (zh) | 一种手性Ni(II)氨基酸希夫碱配位聚合物及其制备方法 | |
WO2022142538A1 (zh) | 一种唑来膦酸钙配合物及其制备方法 | |
WO2022142539A1 (zh) | 一种米诺膦酸钙配合物及其制备方法 | |
Wang et al. | Stepwise coordination assembly approach toward aluminum-lanthanide-based compounds | |
Tanase et al. | Mono-and Dinuclear Zinc Complexes of XDK, H2XDK= m-Xylenediamine Bis (Kemp's triacid imide), and Their Reaction with Phosphate Esters | |
CN112707934A (zh) | 一种阿仑膦酸钙配合物及其制备方法 | |
Ruf et al. | A new pyrazolylborate zinc hydroxide complex capable of cleaving esters, amides and phosphates | |
Sun et al. | Capturing a Metastable Silver (I) Compound of Pyrazine-2, 3-dicarboxylic Acid | |
Gan et al. | A three-dimensional framework structure constructed from 2-(2-pyridyl-N-oxide) ethylphosphonic acid and Nd (III) | |
CN109096314A (zh) | (–)-4,5-蒎烯-2,2′-联吡啶硝酸铜单核手性配合物及其制备方法 | |
Samanamu et al. | Convenient synthesis of aluminum and gallium phosphonate cages | |
CN112625260A (zh) | 一种英卡膦酸钙配合物及其制备方法 | |
CN112724172A (zh) | 一种利塞膦酸钙配合物及其制备方法 | |
CN110551293A (zh) | 3,4-乙撑二氧基噻吩-2,5-二羧酸锌配合物及其制备方法 | |
CN113321816A (zh) | 一种咪唑并吡啶双膦酸钙配合物及其制备方法 | |
CN112341629A (zh) | 使用内循环旋转填充床制备纳米金属-有机框架材料的方法 | |
Gao et al. | Crystal structure and anti-cancer activity of a novel mixed-ligand complex [Pd (Phen)(Phe)] Cl· H 2 O | |
CN110734554A (zh) | 一种Zn(II)三维混配配位聚合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210413 |
|
RJ01 | Rejection of invention patent application after publication |